181 related articles for article (PubMed ID: 6203549)
1. The influence of L-asparaginase therapy on the fibrinolytic system.
Vellenga E; Kluft C; Mulder NH; Wijngaards G; Nieweg HO
Br J Haematol; 1984 Jun; 57(2):247-54. PubMed ID: 6203549
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
3. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
[TBL] [Abstract][Full Text] [Related]
5. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
[TBL] [Abstract][Full Text] [Related]
6. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
7. Modified crossed immunoelectrophoresis to study with whole plasma the reversible complex formation of histidine-rich glycoprotein with plasminogen.
Kluft C; Los P
Thromb Haemost; 1988 Dec; 60(3):411-4. PubMed ID: 2467400
[TBL] [Abstract][Full Text] [Related]
8. Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors.
Walker JB; Bajzar L
J Thromb Haemost; 2007 Jun; 5(6):1257-64. PubMed ID: 17389009
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
10. A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin.
Kluft C; Vellenga E; Brommer EJ; Wijngaards G
Blood; 1982 Jun; 59(6):1169-80. PubMed ID: 6177359
[TBL] [Abstract][Full Text] [Related]
11. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia.
Appel IM; Hop WC; van Kessel-Bakvis C; Stigter R; Pieters R
Thromb Haemost; 2008 Aug; 100(2):330-7. PubMed ID: 18690355
[TBL] [Abstract][Full Text] [Related]
12. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy.
Nowak-Göttl U; Rath B; Binder M; Hassel JU; Wolff J; Husemann S; Ritter J
Haematologica; 1995; 80(5):451-3. PubMed ID: 8566890
[TBL] [Abstract][Full Text] [Related]
13. Antithrombin III, plasminogen, plasmin, and alpha-2-antiplasmin in donor blood and plasma components.
McRoyan DK; McRoyan CJ; Sauter KL; Liu PI; Daniel SJ
Ann Clin Lab Sci; 1985; 15(2):165-70. PubMed ID: 3158265
[TBL] [Abstract][Full Text] [Related]
14. Unbalanced coagulation-fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukaemia.
Semeraro N; Montemurro P; Giordano P; Schettini F; Santoro N; De Mattia D; Giordano D; Conese M; Colucci M
Thromb Haemost; 1990 Aug; 64(1):38-40. PubMed ID: 2274927
[TBL] [Abstract][Full Text] [Related]
15. [Changes of fibrinolysis during labour with and without aprotinin application].
Kühnert M; Stein W; Tekesin I; Hellmeyer L; Schmidt S
Z Geburtshilfe Neonatol; 2003; 207(3):90-100. PubMed ID: 12891467
[TBL] [Abstract][Full Text] [Related]
16. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor.
Korninger C; Collen D
Thromb Haemost; 1981 Oct; 46(3):662-5. PubMed ID: 6171907
[TBL] [Abstract][Full Text] [Related]
18. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance.
Carpenter SL; Mathew P
Haemophilia; 2008 Nov; 14(6):1250-4. PubMed ID: 19141165
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and secretion of the fibrinolytic components, including alpha 2-antiplasmin, by a human hepatoma cell line.
Fair DS; Plow EF
J Lab Clin Med; 1983 Mar; 101(3):372-84. PubMed ID: 6186756
[TBL] [Abstract][Full Text] [Related]
20. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
Agren A; Wiman B; Schulman S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
